BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Sunday, March 15, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 19, 2010
View Archived Issues
Anvyl claims new allosteric modulators of nicotinic acetylcholine receptor alpha7
Read More
New antimalarial agents presented by 4SC
Read More
Czech scientists disclose new cell division protein kinase inhibitors
Read More
RaQualia discovers new CB2 receptor agonists
Read More
Roche identifies new inhibitors of GlyT-1
Read More
Crystal Biopharmaceutical describes new HDAC inhibitors
Read More
Abbott begins ABT-267 trial in healthy volunteers and patients with hepatitis C
Read More
Xenon Pharma begins phase II XEN-402 trial in postherpetic neuralgia
Read More
GSK describes mechanism of new antibacterial agent GSK-299423
Read More
Urocortin-2 has long-term beneficial effects in model of myocardial infarction
Read More
Add-on vandetanib to docetaxel improves progression-free survival in NSCLC
Read More
Combination of three transcription factors reprograms fibroblasts into cardiomyocytes
Read More
FDA grants NX-001 orphan drug status for prevention of delayed kidney graft function
Read More
Biogen Idec and Knopp Neurosciences collaborate on dexpramipexole for ALS
Read More
Repros seeks meeting with FDA to discuss phase III Androxal protocol
Read More
Intellect Neurosciences locks database for phase Ib OX-1 trial
Read More
FDA grants Urigen Pharmaceuticals type C meeting for URG-101
Read More
CSL Behring receives FDA approval to extend shelf life of Hizentra
Read More
Quark Pharma and Novartis enter into licensing option agreement for QPI-1002
Read More
Shire withdraws NDA for ProAmatine
Read More
BioMarin acquires ZyStor Therapeutics and its lead product ZC-701
Read More
Chugai provides update on R&D developments
Read More
Clavis begins enrollment in phase III trial of elacytarabine in late-stage AML
Read More
FDA grants priority review to ipilimumab in previously treated advanced melanoma
Read More
FDA grants orphan status to lorvotuzumab mertansine for small cell lung cancer
Read More
